Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Super-enhancer-driven PPP1R15B/CReP, regulated by C/EBPβ and YY1, is oncogenic in multiple myeloma

ABSTRACT: Super-enhancer-driven PPP1R15B/CReP, regulated by C/EBPβ and YY1, is oncogenic in multiple myeloma

PROVIDER: PRJNA1109325 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21683860_1.fastq.gz	Fastqsanger.gz
	SRR21683860_2.fastq.gz	Fastqsanger.gz
	SRR21683861_1.fastq.gz	Fastqsanger.gz
	SRR21683861_2.fastq.gz	Fastqsanger.gz
	SRR21683862_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 32

Similar Datasets

Super-enhancer-driven PPP1R15B/CReP, regulated by C/EBPβ and YY1, is oncogenic in multiple myeloma

Project description:Super-enhancer-driven PPP1R15B/CReP, regulated by C/EBPβ and YY1, is oncogenic in multiple myeloma

| PRJNA881324 | ENA

Super-enhancer-driven PPP1R15B/CReP, regulated by C/EBPβ and YY1, is oncogenic in multiple myeloma [HiChIP I]

Project description:Super-enhancer-driven PPP1R15B/CReP, regulated by C/EBPβ and YY1, is oncogenic in multiple myeloma [HiChIP I]

| PRJNA883643 | ENA

Super-enhancer-driven PPP1R15B/CReP, regulated by C/EBPβ and YY1, is oncogenic in multiple myeloma [HiChIP II]

Project description:Super-enhancer-driven PPP1R15B/CReP, regulated by C/EBPβ and YY1, is oncogenic in multiple myeloma [HiChIP II]

| PRJNA1109331 | ENA

Super-enhancer-driven PPP1R15B/CReP, regulated by C/EBPβ and YY1, is oncogenic in multiple myeloma

Project description:We identified a novel super-enhance-driven oncogene PPP1R15B overexpressed in multiple myeloma as compared to normal plasma cells and B lymphoma cells. We used PPP1R15B specific shRNAs to study its function.

2024-06-25 | GSE213556 | GEO

Super-enhancer-driven PPP1R15B/CReP, regulated by C/EBPβ and YY1, is oncogenic in multiple myeloma [HiChIP I]

Project description:H3K27ac HiChIP analysis was performed in two multiple myeloma cell lines to analyze active chromatin-chromatin interactions in myeloma.

2024-06-25 | GSE214018 | GEO

Super-enhancer-driven PPP1R15B/CReP, regulated by C/EBPβ and YY1, is oncogenic in multiple myeloma [HiChIP II]

Project description:H3K27ac HiChIP analysis was performed in multiple myeloma cell lines and primary sample to analyze active chromatin-chromatin interactions in myeloma.

2024-06-25 | GSE267003 | GEO

Super-enhancer-driven PPP1R15B/CReP, regulated by C/EBPβ and YY1, is oncogenic in multiple myeloma

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-06-25 | GSE267004 | GEO

Biomarker discovery and subtype classification within Multiple Myeloma by Super-SILAC

Project description:Multiple Myeloma (MM) is the second most prevalent blood cancer (10%) after non-Hodgkin's lymphoma and represents approximately 1% of all cancers and 2% of all cancer deaths. MM is a complex disease characterized by numerous genetic alterations and recent mRNA profiling studies have attempted to subclassify the disease to build pathogenetic and prognostic models Correct classification of cancer patients into subtypes is a prerequisite for acute diagnosis and effective treatment. Here we use high accuracy, quantitative proteomics to segregate cancer subtypes directly at the level of expressed proteins. Multiple myeloma is a heterogeneous disease in its initial clinical features as well as its outcome. We investigated two subtypes of Multiple Myeloma: multiple myeloma associated with t(4;14) chromosomal translocation as well as t(4;14)-negative MM subtype. The t(4;14) translocation, found in 15% of multiple myeloma cases, indicates a poor prognosis. Super-SILAC mix was combined of cell lysates from 8 diverse cell lines labelled with heavy amino acids (Lys8 and Arg10). The Super-SILAC library is mixed with samples (lysates), and quantitative mass spectrometric analysis is performed using a setup consisting of LC and on a linear ion trap Orbitrap mass spectrometer with high mass accuracy at the MS and MS/MS levels. This way we have analysed 20 patient samples from present MM. Shotgun proteomic analysis yielded a proteome of more than 5300 quantified proteins overall (3000 on an average per individual sample). High accuracy of quantification allowed robust separation of subtypes by hierarchical clustering on the protein level.

2024-07-15 | PXD003138 | Pride

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

Project description:Chromatin regulators have become highly attractive targets for cancer therapy, yet many of these regulators are expressed in a broad range of healthy cells and contribute generally to gene expression. An important conundrum has thus emerged: how can inhibition of a general regulator of gene expression produce selective effects at specific oncogenes? Here we investigate how inhibition of the transcriptional coactivator BRD4 (Bromodomain containing 4) leads to selective inhibition of disease-critical oncogenes in a highly malignant blood cancer, multiple myeloma (MM). We found that BRD4 generally occupies the promoter elements of active genes together with the Mediator coactivator, but remarkably high levels of these two coactivator proteins were associated with a small set of exceptionally large enhancers. These super-enhancers are associated with genes that feature prominently in MM biology, including the MYC oncogene. Treatment of MM tumor cells with the BET-bromodomain inhibitor JQ1 led to preferential loss of BRD4 at super-enhancers and consequent transcription elongation defects that preferentially impact genes with super-enhancers, including the c-MYC oncogene. Super-enhancers were found at key oncogenic drivers in many other tumor cells. Thus, super-enhancers can regulate oncogenic drivers in tumor cells, which in some cells can be preferentially disrupted by BRD4 inhibition, which in turn contributes to the selective transcriptional effects observed at these oncogenes. These observations have implications for the discovery of novel cancer therapeutics directed at components of super-enhancers in diverse tumor types. ChIP-Seq for chromatin regulators and RNA Polymerase II in multiple myeloma, glioblastoma multiforme, and small cell lung cancer

2013-01-02 | E-GEOD-42355 | biostudies-arrayexpress

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers [Affymetrix]

Project description:Chromatin regulators have become highly attractive targets for cancer therapy, yet many of these regulators are expressed in a broad range of healthy cells and contribute generally to gene expression. An important conundrum has thus emerged: how can inhibition of a general regulator of gene expression produce selective effects at specific oncogenes? Here we investigate how inhibition of the transcriptional coactivator BRD4 (Bromodomain containing 4) leads to selective inhibition of disease-critical oncogenes in a highly malignant blood cancer, multiple myeloma (MM). We found that BRD4 generally occupies the promoter elements of active genes together with the Mediator coactivator, but remarkably high levels of these two coactivator proteins were associated with a small set of exceptionally large enhancers. These super-enhancers are associated with genes that feature prominently in MM biology, including the MYC oncogene. Treatment of MM tumor cells with the BET-bromodomain inhibitor JQ1 led to preferential loss of BRD4 at super-enhancers and consequent transcription elongation defects that preferentially impact genes with super-enhancers, including the c-MYC oncogene. Super-enhancers were found at key oncogenic drivers in many other tumor cells. Thus, super-enhancers can regulate oncogenic drivers in tumor cells, which in some cells can be preferentially disrupted by BRD4 inhibition, which in turn contributes to the selective transcriptional effects observed at these oncogenes. These observations have implications for the discovery of novel cancer therapeutics directed at components of super-enhancers in diverse tumor types. Gene expression profiling in multiple myeloma cells after BET-Bromodomain inhibition with JQ1

2013-03-07 | E-GEOD-44929 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data